Search results
Results From The WOW.Com Content Network
AstraZeneca plc ( / ˌæstrəˈzɛnəkə /) ( AZ) is a British-Swedish multinational pharmaceutical and biotechnology company [ 2 ][ 3 ][ 4 ] with its headquarters at the Cambridge Biomedical Campus in Cambridge, England. [ 5 ] It has a portfolio of products for major diseases in areas including oncology, cardiovascular, gastrointestinal ...
The Oxford–AstraZeneca COVID‑19 vaccine, sold under the brand names Covishield [31] and Vaxzevria [1] [32] among others, is a viral vector vaccine for the prevention of COVID-19. It was developed in the United Kingdom by Oxford University and British-Swedish company AstraZeneca , [ 33 ] [ 34 ] [ 35 ] using as a vector the modified ...
Alexion Pharmaceuticals, Inc. Alexion Pharmaceuticals, Inc., a subsidiary of AstraZeneca, is a pharmaceutical company headquartered in Boston, Massachusetts that specializes in orphan drugs to treat rare diseases . Its products include eculizumab (Soliris) and ravulizumab (Ultomiris), both used to treat the rare disorders of atypical hemolytic ...
AstraZeneca’s COVID-19 vaccine provided strong protection against sickness and eliminated hospitalizations and deaths from the disease across all age groups in a late-stage study in the United ...
The U.S. Food and Drug Administration (FDA) on Thursday approved Ionis Pharmaceuticals and partner AstraZeneca's drug to treat nerve damage caused by a life-shortening rare disease. The drug ...
Imfinzi clocked $4.24 billion in sales in 2023, and is a blockbuster medicine in AstraZeneca's key oncology portfolio, which makes up more than 20% of its total revenues. ... Photos of the 2024 ...
Pages in category "Drugs developed by AstraZeneca" The following 23 pages are in this category, out of 23 total. This list may not reflect recent changes. A.
The Oxford–AstraZeneca COVID-19 vaccine, sold under the brand names Vaxzevria[6]and Covishield,[7]is a viral vector vaccine[8]produced by the British University of Oxford, British-Swedish company AstraZeneca, and the Coalition for Epidemic Preparedness Innovations. [8][9][10]Finland, Denmark, and Norway suspended the use of the Oxford ...